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Abstract
Background: Enzyme replacement therapy (ERT; alglucosidase alfa) has improved the prospects for patients with
classic infantile Pompe disease considerably. However, over time we noticed that many of these children exhibit
distal muscle weakness at an early age, which is in contrast to the primarily proximal and axial muscle weakness in
patients with late-onset Pompe disease. This was reason to study the prevalence and severity of distal muscle
weakness, and the sequence of muscle involvement over time in patients that had learned to walk under ERT.
Methods: In this prospective, single-center cohort study, we studied 16 classic infantile patients. We used video
recordings that were made during regular standardized assessments to investigate distal muscle function (active
dorsiflexion of the feet during walking; ability to use a pincer grasp/actively extend the fingers) and proximal
muscle function (standing up from a supine position; raising the arms above the head).
Results: Median age at start of ERT was 3.2 months (0.1–5.8 months), median age at study end was 5.6 years (2.9–
18.2 years). Six patients (6/16, 38%) initially had no evident signs of distal muscle weakness and developed a gait
with active dorsiflexion of the feet. The other 10 patients never exhibited active dorsiflexion of the feet during
walking. At study-end two patients showed no loss of distal muscle function. A subset of five patients (5/16, 31%)
developed also weakness of the hands, particularly of the extensors of the 3rd and 4th digit.
Conclusions: We found that the majority (14/16, 88%) of patients who had learned to walk exhibited distal muscle
weakness of the lower extremities, while a subset (5/16, 31%) also developed weakness of the hands. The distal
muscle weakness was often more serious than, and preceded the development of, the proximal muscle weakness.
Keywords: Pompe disease, Glycogen storage disease type II, Enzyme replacement therapy (ERT), Muscle function,
Distal muscle weakness
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Background
Pompe disease (glycogen storage disease type II, OMIM
#232300) is a rare metabolic disorder caused by the defi-
ciency of acid α-glucosidase, leading to lysosomal
glycogen accumulation in many tissues, particularly in
muscle [1]. Pompe disease encompasses a continuous
spectrum, varying from a relentlessly progressive classic
infantile phenotype to a less progressive, ‘milder’ late-
onset phenotype [2, 3]. Classic infantile Pompe disease is
characterized by progressive, generalized, muscle weak-
ness manifesting shortly after birth, accompanied by a
typical hypertrophic cardiomyopathy. Untreated, patients
die before 1 year of age due to cardio-respiratory insuffi-
ciency [4, 5]. Limb-girdle muscle weakness and respira-
tory dysfunction are the hallmarks of the late-onset
phenotype, leading to wheelchair and/or respirator de-
pendency in many patients [2, 6–8].
In classic infantile Pompe disease, enzyme-replacement
therapy (ERT) with recombinant human acid α-
glucosidase (rhGAA, alglucosidase alfa) has shown to im-
prove – ventilator-free – survival, reverse the cardiac
hypertrophy, and improve patients’ muscle function,
enabling them to reach previously unmet motor mile-
stones such as standing and walking [9–14]. However,
remarkably, also many otherwise very ‘good-respond-
ing’ ERT-treated classic infantile patients exhibit re-
sidual muscle weakness. Over the years, we noticed
that this muscle weakness was not limited to the
proximal muscles – typically seen in the late-onset
phenotype in children and adults – but also involved
the distal muscles of the feet [15]. This new pheno-
type comprising proximal and distal muscle weakness,
was also noted by several other authors [16–18].
Presently, it is still unclear which percentage of pa-
tients develop this distal weakness, at what age this starts
to develop, and how it relates to the development of
proximal muscle weakness. Furthermore, it is unknown
whether this distal weakness is limited to the lower ex-
tremities, or involves also the upper extremities, i.e. the
hand musculature. Since we have regularly recorded all
motor assessments on video from the start of ERT, we
had the unique opportunity to study this intriguing
question.
Results
Patients
Of the 22 patients with classic infantile Pompe disease
that were seen in our Center during the study period, 16
(72%) had learned to walk, and were thus included in
this study (Table 1). The most common disease causing
variants (www.pompevariantdatabase.nl) were c.del525T
(7 patients, 3/7 homozygous) and c.2481 + 102_2646 +
31del (6 patients, 3/6 homozygous). Median age at start
of ERT was 3.2 months (0.1–5.8 months), median age at
study end was 5.6 years (2.9–18.2 years). Echocardiog-
raphy showed hypertrophic cardiomyopathy in all
patients pre-ERT, with median left ventricular mass
index (LVMI) 210 g/m2 (range 98–756) and median z-
score 19 (range 5–88). During follow-up two patients
became ventilator dependent (pat 4 and 11, respective
age 2.7 and 2.0 years) after recurrent respiratory infec-
tions. Four patients were cross-reactive immunological
material (CRIM) negative (pat. 10, 11, 15, 16), one of
whom died at the age of 4.4 years due to respiratory fail-
ure. The remaining 15 patients were alive at study end.
Video analyses of motor function
Lower extremities (Fig. 1a; Table 1)
Ten patients (63%) showed moderate to severe distal
muscle weakness from the beginning. As a result, they
never developed a walking gait, with active dorsiflexion
of the feet resulting in a heelstrike. The best achieve-
ment in these patients was a walking pattern with a mid/
forefoot landing. Six patients (37%) initially had no evi-
dent signs of distal muscle weakness: they developed a
heelstrike-gait at a median age of 3.0 years (range 2.8–
3.5 years).
With regard to proximal muscle function, nine pa-
tients (56%) were at any point in time able to rise from a
supine position without any visible difficulty or use of
external support. The other seven patients (44%) always
showed some signs of proximal muscle weakness,
reflected by a Gowers sign or Trendelenburg gait. There
were no differences regarding the age at which patients
had learned to stand and walk between the patients with
or without proximal muscle weakness.
The six patients who initially had no distal muscle
weakness also had normal proximal muscle function in
the beginning. At the end of the study, four of these pa-
tients had reverted to a mid/forefoot landing during
walking: three had lost their heelstrike-gait (at age 3.6,
4.0 and 5.0 years) but still had no signs of proximal
muscle weakness, while one had developed distal muscle
weakness (at age 4.0 years), before also developing prox-
imal muscle weakness (at age 8.1 years). Only two of the
16 patients (13%) had no distal weakness at their last as-
sessment at the ages of 2.9 and 4.0 years. They also had
no signs of proximal muscle weakness (Table 1).
Of the other 10 patients, at study end, one had normal
proximal muscle function but impaired ankle dorsiflexion,
four were still able to walk but with evidence of both prox-
imal and distal muscle weakness, while five had lost the
ability to stand and walk and had become wheelchair
bound due to severe overall muscle weakness.
Dosing and CRIM status
Only one of the five patients (20%) who were initially
treated with a lower dose of recombinant enzyme
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Fig. 1 (See legend on next page.)
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achieved a walking pattern without apparent distal and
proximal muscle weakness, while five of the 11 patients
(45%) treated with 40mg/kg/week initially showed no
muscle weakness of either distal or proximal muscles.
One of the CRIM negative patients (1/4, 25%; treated
with 40 mg/kg/week from the start, additional immuno-
modulation) and 5/12 (42%) of the CRIM positive pa-
tients initially achieved a walking pattern with a normal
heelstrike-gait.
Upper extremities (Fig. 1b; Table 1)
All patients acquired the ability to fully raise their arms
above the head and obtained normal fine motor skills, as
was evidenced by a normal pincer grasp when picking
up small objects (achieved at median age 1.6 years, range
1.0–3.0). During follow-up, three patients developed
profound finger extensor weakness mainly of the third
and fourth digit (patients 2, 4, and 5; Fig. 2b). These
three patients also developed weakness of the upper
arms at a later stage. Two other patients also developed
some distal muscle weakness reflected by a more crude
grip using the whole hand, one of whom had no signs of
upper-arm weakness, while in the other patient loss of
proximal and distal arm function had coincided with a
fracture of the clavicle. The other 11 patients had exhib-
ited no visible impairment of upper-arm and hand func-
tion at the end of follow-up. Weakness of the upper
extremities was seen only in patients with severe prox-
imal and distal weakness of the lower extremities at an
earlier stage.
Other motor features
Early motor function development
Patients were able to stand and walk independently at
the respective median ages of 1.0 (range 0.8–1.4) and
1.4 years (range 1.0–1.8), which was within the 90th per-
centile of healthy age-matched controls in 8/16, 50%
(standing) and 13/16, 81% (walking) of patients.
Functional motor development, as reflected by their
AIMS and BSIDII scores, showed a gradual improve-
ment after start of ERT. At their last BSIDII evaluation,
9/16, 56% of patients reached an age-equivalent score,
reflecting normal development (Data not shown).
Supportive measures
Due to decreased ankle dorsiflexor strength (Fig. 2a),
nine patients eventually needed supportive measures.
Seven patients (pat 2–5, 7, 13, 15) used splints at night
(See figure on previous page.)
Fig. 1 Proximal and distal muscle function in ERT-treated classic infantile Pompe patients. a Proximal and distal muscle function of the lower
extremities. Upper column: the ability to come to stand from supine, as a parameter for proximal muscle strength of the legs. Lower column:
active dorsiflexion of the feet, reflected in the ability to perform a heel-strike during walking. b Proximal and distal muscle function of the upper
extremities. Upper column: raising arms above head as parameter for proximal muscle function. Lower column: the ability to use a pincer grasp,
while performing fine motor tasks
Fig. 2 Distal muscle weakness of the feet and hands in ERT-treated classic infantile Pompe patients. a Severe weakness of foot dorsiflexor
muscles, patient was asked to perform active dorsiflexion of the foot. b Weakness of finger extensor muscles, with characteristic positioning of
the 3rd and 4th digit. Picture was taken at maximal finger extension
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to increase ankle mobility and prevent contractures
(start use splints between 2.5 and 8.0 years), while five
patients (pat 1–3, 5, 10) used ankle foot orthoses to pro-
vide support when walking (start use foot orthoses be-
tween 1.8 and 9.0 years). Three patients (pat 2, 3, 5) used
both splints and ankle foot orthoses. With these mea-
sures, we were able to maintain at least 90 degree ankle
dorsiflexion angle in ambulant patients. None of the pa-
tients underwent surgery for contractures or other foot
deformities. One patient (pat 2) used a hand splint (from
age 5.6 years) to support hand function and prevent
contractures.
Discussion
Long-term survival of classic infantile Pompe patients
treated with ERT has unveiled a specific phenotype. We
studied the occurrence and sequence of involvement of
distal and proximal muscle weakness in 16 patients with
classic infantile Pompe disease. Although all patients
learned to walk, we found that: 1) 88% of patients devel-
oped distal muscle weakness of the lower extremities at
any point in time, 2) 31% of patients developed also
weakness of the hands, particularly of the extensors of
the 3rd and 4th digit, and 3) patients exhibited a specific
pattern of muscle involvement, in which distal muscle
weakness of the lower extremities was more serious than
and preceded proximal muscle weakness; likewise, weak-
ness of the hands occurred earlier than that of the
upper-arms.
Early motor development showed significant improve-
ment after start of ERT, which enabled patients to
achieve motor milestones such as standing and walking.
Many patients even learned to walk at a normal age
compared to their peers.
However, over time, 14 of the 16 patients (88%) devel-
oped distal weakness of the legs. Importantly, most pa-
tients never developed a walking pattern with active foot
dorsiflexion (10/16; 63%): six patients (37%) initially de-
veloped a normal heelstrike-gait, four of whom displayed
secondary progressive weakness of the distal muscle
groups. Only 2 patients – still relatively young (2.9 and
4.3 years) – had a normal heelstrike-gait at the end of
follow-up. In our study, all patients above the age of 5
years exhibited distal muscle weakness. From a func-
tional point of view, the distal muscle weakness was in
most cases even more severe than the accompanying
proximal muscle weakness. Compared to healthy peers,
the development of a mature gait with a heelstrike was
delayed in all patients (≈1.5 years against 3.0 years) [19].
There are only few reports in the literature on the oc-
currence of distal muscle weakness in long-term treated
classic infantile patients. In one retrospective study [17]
nine out of 11 treated classic infantile patients, median
age 8.0 years (range 5.4–12.0), developed dorsiflexor
weakness of the feet. The age at which this distal weak-
ness occurred, or the pattern in which distal and prox-
imal weakness developed, was not reported. Two
patients did not show any dorsiflexor weakness (age 5.4
and 8.2 years at study-end). A recent case study reports
subacute – over several months – development of dorsi-
flexor weakness at an older age (6.5 years), attributed to
progressive myopathy and possibly also minor peripheral
nerve involvement [20].
To our knowledge, weakness of the hand musculature
has not been reported in earlier studies. We found that
weakness of the upper extremities, including weakness
of hand musculature was less prominent and occurred
only in patients with severe weakness of lower extrem-
ities. Three of the five patients with hand-weakness had
a particular positional tendency with flexion of the third
and fourth finger. This may result from the fact that
third and fourth digit are controlled by only one finger
extensor muscle, contrary to the other digits [21].
We found that motor outcome differed between pa-
tients. Several factors, including age at start of treatment
[9, 10], ERT dose [15] and CRIM status [22, 23], have
shown to be of influence on survival and motor out-
come. In our study, patients who were treated initially
with a lower dose more frequently showed persistent
weakness of foot dorsiflexion, compared to patients
treated with 40mg/kg/week. This better outcome in the
higher-dose group is in accordance with our earlier find-
ings [15]. The influence of CRIM status on motor out-
come was less apparent. However, it should be noted
that the follow-up of the CRIM negative patients was
shorter.
The severe and early distal weakness that we have found
is discrepant with the predominant limb-girdle and axial
weakness seen in children and adults with late-onset
Pompe disease. Involvement of dorsiflexor muscles of the
feet or specific involvement of the hand musculature does
typically not occur in those patients until end-stage dis-
ease [6, 7, 24, 25]. Only one case of adult Pompe disease
has been described, in which weakness of wrist extensor
muscles was one of the presenting symptoms [26].
The pathophysiological process underlying the distal
muscle weakness is still not fully understood. Several
factors might play a role, including extensive involve-
ment of distal muscles in the myopathic process [20,
27], and potential neurogenic involvement due to
glycogen storage in the central [28–30] and peripheral
nervous system [20, 31, 32]. Detailed radiological, elec-
trodiagnostic and histological studies in larger numbers
of patients are needed to provide a better understanding
of the underlying etiology.
Our study had several limitations. Despite a relatively
large cohort size of classic infantile patients, the absolute
number of subjects is still small. Although we would
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have liked to provide a more quantitative measure of
muscle strength, such as manual muscle testing or hand
held dynamometry, to strengthen our opinion on the de-
gree of distal versus proximal weakness, these measures are
notably unreliable in young children. Additionally, a formal
gait analysis studying kinematics of additional muscle joints
could have provided more detailed information.
Since we recorded all assessments on video from the
beginning, we were able to precisely look at when the
distal muscle weakness developed. Loss of ankle dorsi-
flexion results in an unstable (steppage) gait, which may
increase the risk of falling and, consequently, occurrence
of fractures. Furthermore, distal muscle weakness may
lead to loss of joint mobility resulting in development of
contractures. Therefore, awareness and early recognition
of distal weakness is important for timely application of
supportive measures such as splints and foot orthoses.
Conclusion
Although many patients now learn to walk under ERT-
treatment, the majority develops distal muscle weakness,
most prominent of the feet but also of the hand muscula-
ture, which is often more serious than, and occurs mostly
prior to development of proximal muscle weakness.
Methods
Patients and study design
This study is part of a prospective, open-label, cohort
study on the long-term effects of enzyme-replacement
therapy in classic-infantile Pompe disease, conducted at
the center for Lysosomal and Metabolic Diseases of
Erasmus MC University Medical Center, the designated
center of expertise for Pompe disease in the
Netherlands. Patients were included if 1) they had a con-
firmed diagnosis of classic-infantile Pompe disease, de-
fined as manifesting muscle weakness within 6 months
of birth, a hypertrophic cardiomyopathy, and two dele-
terious disease-causing variants in the acid-α-glucosidase
gene (GAA), and 2) had learned to walk independently.
The earliest data that were used for the purpose of this
study are from 1999, database lock was December 31st
2016. Informed consent was obtained from the parents
of all patients. From 2009 onward, we treated newly di-
agnosed patients with recombinant human enzyme
(rhGAA; alglucosidase alfa) at a dose of 40 mg/kg/week
from the start. Before that, some patients had initially
been treated by recombinant enzyme from transgenic
rabbits or with a lower dose of 20 mg/kg/2 weeks; for all
patients initially receiving 20 mg/kg/2 weeks, between
2009 and 2014 their dose of alglucosidase alfa was in-
creased to 40mg/kg/week. Immunomodulation in an
ERT-naïve setting with Rituximab (RTX), Methotrexate
(MTX) and intravenous immunoglobulins (IVIG) was
initiated in 2012, in newly diagnosed patients older than
2months of age at time of diagnosis. (See for details
Poelman et al., 2018) [33].
Procedures
Video analyses of motor function
To investigate the occurrence and severity of distal muscle
weakness, and the sequence of muscle involvement, we
used video recordings of the regularly performed stan-
dardized clinical assessments (AIMS, BSID-II, Quick
motor function test (QMFT), Six-minute walk test
(6MWT) and timed tests: running 10m, standing up from
supine position (TT)) to construct an overview of the
motor development of the patients through time. This re-
sulted in a 4-h summary (= total for all patients) of video
material obtained from 122 h of film, comprising 481 clin-
ical assessments. Video recordings were analyzed every 3
months until the age of 1 year, twice a year between 1 to
3 years of age, and once a year from the age of 3 onwards.
From these video recordings we assessed the following
to investigate distal muscle function: (1) active dorsiflexion
of the feet during walking resulting in a heel-strike (yes /
no) and; (2) weakness of the hands and fingers: ability to
use a pincer grasp (yes / no) and being able to actively ex-
tend the fingers (yes / no). Proximal muscle weakness was
evaluated by assessing (1) coming to stand from a supine
position (without difficulty / visible difficulty but without
external support (Gowers maneuver) / only with external
support (e.g. chair/table) / not able) and (2) raising arms
above the head in a straight position (able / not able).
All video material was scored by three independent ex-
aminers with experience in pediatrics and/or neuromus-
cular disorders. If no consensus was reached, results
were discussed, and agreed upon in a consensus meeting
(JvdD and NvdB).
Other motor features
Additional investigations to describe overall early motor
function development comprised 1) motor milestones
(independent sitting, standing, and walking), 2) the Al-
berta Infant Motor Scale (AIMS), and 3) Bayley Scales of
Infant Development II (BSID-II). Established reference
values were used to compare patients with age-matched
controls [34–36]. Furthermore, we collected information
on the timing and type of supportive measures for foot
dorsiflexion and prevention of joint contractures, as well
as the use of hand splints to support hand functioning.
Statistical analyses
Due to the small number of patients no comparative sta-
tistics were applied. Descriptive statistics, including me-
dian and range, were used to summarize demographic
and clinical data (SPSS for Windows (version 24, IBM
Corp, Armonk, NY). For comparison with healthy peers,
established reference values were used.
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